# US 2016/0258871 A1 · Method of detecting bladder cancer by optical analysis of bodily fluids

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0258871 A1
- Document ID: US20160258871A1
- Status: Published application
- Kind: A1
- Application number: 14/641,238
- Filed: 2015-03-06
- Published: 2016-09-08
- Earliest claimed: 2015-03-06
- Assignees: King Saud University
- Applicants: King Saud University
- Inventors: VADIVEL MASILAMANI; MOHAMAD SALEH ALSALHI; KARIM HAMDA FARHAT; DANNY MONTHER RABAH; SARADH PRASAD; SANDHANASAMY DEVANESAN
- Web page: https://patentgrep.com/patent/US20160258871A1

## CPC

- G01N 21/6486: {Measuring fluorescence of biological material, e.g. DNA, RNA, cells (G01N21/6428 takes precedence)}
- G01N 21/03: Cuvette constructions
- G01N 21/6402: {Atomic fluorescence; Laser induced fluorescence}
- G01N 33/49: Blood {(chemical methods for determining blood cell populations G01N33/5094; chemical analysis of blood groups or blood types G01N33/80)}
- G01N 33/493: urine
- G01N 2201/06113: Coherent sources; lasers
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The method of detecting bladder cancer by optical analysis of bodily fluids utilizes optical techniques to determine a concentration of porphyrin in a patient's bodily fluid sample. The patient is administered 5-aminolevulinic acid and, approximately eight hours later, a bodily fluid sample is collected from the patient, and this bodily fluid sample is optically analyzed to measure a concentration of porphyrin therein. Optical analysis is preferably performed by laser-induced fluorescence spectroscopy. If the measured concentration of porphyrin is approximately three times a pre-determined porphyrin concentration for a healthy person of the same age as the patient, then the patient is diagnosed with bladder cancer.

## Claims

### Claim at position 1

1-7. (canceled)

### Claim 8

A method of detecting bladder cancer by optical analysis of bodily fluids, comprising the steps of:
administering to a patient, approximately 5 mg of 5-aminolevulinic acid to a patient per kilogram of the body weight of the patient;
collecting a bodily fluid sample from the patient;
wherein the bodily fluid sample is selected from the group consisting of a urine sample and a blood sample;
performing laser-induced fluorescence spectroscopy on the bodily fluid sample to measure a concentration of porphyrin therein;
wherein the laser-induced fluorescence spectroscopy including collimating a laser having a power rating about 100 mW, and a wavelength about 405 nm, through the bodily fluid sample, collecting a dispersed laser exiting the bodily fluid sample via a photodiode array, converting into an electrical signal, and amplifying the electrical signal, converting the amplified electrical signal from an analog signal to a digital signal, processing the digital signal with a digital signal processor, and displaying the concentration of porphyrin detected therein; and
diagnosing the patient with bladder cancer if the measured concentration of porphyrin is approximately three times a pre-determined porphyrin concentration for a healthy person of the same age as the patient.

### Claim 9

(canceled)

### Claim 10 (depends on 8)

The method of detecting bladder cancer by optical analysis of bodily fluids as recited in claim 8, wherein the step of administering the 5-aminolevulinic acid to the patient comprises orally administering the 5-aminolevulinic acid to the patient.

### Claim at position 5

11-12. (canceled)

### Claim 13 (depends on 8)

The method of detecting bladder cancer by optical analysis of bodily fluids as recited in claim 8, wherein the step of collecting the bodily fluid sample from the patient is performed approximately eight hours after the step of administering the 5-aminolevulinic acid to the patient.

### Claim 14

A method of detecting bladder cancer by optical analysis of bodily fluids, comprising the steps of:
administering 5-aminolevulinic acid to a patient;
wherein the administering includes approximately 5 mg of the 5-aminolevulinic acid per kilogram of the body weight of the patient;
collecting a bodily fluid sample from the patient approximately eight hours after administering the 5-aminolevulinic acid to the patient;
optically analyzing the bodily fluid sample to measure a concentration of porphyrin therein;
wherein the step of optically analyzing the bodily fluid consists of performing laser-induced fluorescence spectroscopy on the bodily fluid sample to measure a concentration of porphyrin therein;
wherein the laser-induced fluorescence spectroscopy including collimating a laser having a power rating about 100 mW, and a wavelength about 405 nm, through the bodily fluid sample, collecting a dispersed laser exiting the bodily fluid sample via a photodiode array, converting into an electrical signal, and processing the electrical signal to ultimately display the concentration of porphyrin detected therein; and
diagnosing the patient with bladder cancer if the measured concentration of porphyrin is approximately three times a pre-determined porphyrin concentration for a healthy person of the same age as the patient.

### Claim 15

(canceled)

### Claim 16 (depends on 14)

The method of detecting bladder cancer by optical analysis of bodily fluids as recited in claim 14, wherein the step of administering the 5-aminolevulinic acid to the patient comprises orally administering the 5-aminolevulinic acid to the patient.

### Claim 17 (depends on 14)

The method of detecting bladder cancer by optical analysis of bodily fluids as recited in claim 14, wherein the step of collecting the bodily fluid sample from the patient comprises collecting a urine sample from the patient.

### Claim 18 (depends on 14)

The method of detecting bladder cancer by optical analysis of bodily fluids as recited in claim 14, wherein the step of collecting the bodily fluid sample from the patient comprises collecting a blood sample from the patient.

### Claim 19

(canceled)

### Claim 20

A method of detecting bladder cancer by optical analysis of bodily fluids, consisting of the steps of:
administering approximately 5 mg of 5-aminolevulinic acid per kilogram of body weight of a patient via oral administration;
collecting a bodily fluid sample from the patient approximately eight hours after administering the 5-aminolevulinic acid to the patient;
wherein the bodily fluid sample is chosen from the group consisting of a blood sample and a urine sample, and has a volume on the order of 5 mL;
optically analyzing the bodily fluid sample by performing laser-induced fluorescence spectroscopy on the bodily fluid sample to measure a concentration of porphyrin therein;
wherein the laser-induced fluorescence spectroscopy including collimating a laser having a power rating about 100 mW, and a wavelength about 405 nm, through the bodily fluid sample, collecting a dispersed laser exiting the bodily fluid sample via a photodiode array, converting into an electrical signal, and processing the electrical signal to ultimately display the concentration of porphyrin detected therein; and
diagnosing the patient with bladder cancer if the measured concentration of porphyrin is approximately three times a pre-determined porphyrin concentration for a healthy person of the same age as the patient.
